rs121965064 — F11 Phe301Leu (Type III)

Ashkenazi Jewish founder missense mutation in coagulation factor XI causing impaired FXI dimerization; homozygotes develop hemophilia C (severe FXI deficiency) with post-surgical and trauma-related bleeding, while heterozygotes have partial deficiency with variable bleeding risk; the most prevalent FXI deficiency allele in Ashkenazi Jewish populations

See your personal result for F11

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Phe301Leu Mutation — When Less FXI Protects Against Strokes

Coagulation factor XI (FXI) is the amplifier of the clotting cascade — it is not needed to start a clot, but it is essential for stabilizing and propagating one. The F11 Phe301Leu variant (historically called Phe283Leu; also referred to as the Type III Ashkenazi founder mutation) disrupts the architecture of the FXI protein itself, slowing the production of functional enzyme to a trickle. In the Ashkenazi Jewish population, this single mutation carries an allele frequency of approximately 2.4% — roughly one in twenty Ashkenazi individuals carries at least one copy.

The clinical consequence is paradoxical: homozygous carriers have insufficient FXI to control mucosal surface bleeding after surgery or injury, yet the same deficiency substantially reduces their lifetime risk of ischemic stroke and deep-vein thrombosis. This paradox has reshaped how hematologists think about the coagulation cascade — and has driven the development of a new class of "hemostasis-sparing" anticoagulant drugs that target FXIa directly.

The Mechanism

The Phe301Leu substitution sits in the fourth apple domain of FXI, a region essential for the protein's dimerization11 the protein's dimerization
FXI normally circulates as a homodimer — two identical subunits held together by non-covalent interactions. Proper dimerization is required for efficient secretion from hepatocytes into the bloodstream. When phenylalanine at position 301 is replaced by the smaller, more flexible leucine, the fourth apple domain cannot fold correctly, and the two subunits fail to form a stable dimer. As a result, roughly 92% of the protein is retained intracellularly — never reaching the bloodstream. The ~8% that does dimerize and secrete is biochemically competent and clots normally; there is simply not enough of it.

This explains a clinically important distinction between Type III and the other Ashkenazi founder mutation (Type II, Glu117Stop/Glu135Stop): Type II produces no FXI protein at all (a complete null allele), while Type III produces a small but functional residual amount. In the original Asakai et al. 1991 study, Type III homozygotes had mean FXI activity of 9.7% of normal, compared to only 1.2% for Type II homozygotes22 Type III homozygotes had mean FXI activity of 9.7% of normal, compared to only 1.2% for Type II homozygotes
Asakai R, Chung DW, Davie EW, Seligsohn U; NEJM 1991;325:153-8; both genotypes cause severe FXI deficiency by clinical definition (<15 U/dL), but the residual activity in Type III may modulate bleeding severity in some individuals.

The Evidence

The epidemiological evidence for cardiovascular protection in severe FXI deficiency is robust and consistent. In a landmark Israeli cohort of 115 patients aged 45+ with severe FXI deficiency33 115 patients aged 45+ with severe FXI deficiency
Salomon O et al., Blood 2008; activity <15 U/dL in all patients; ischemic stroke expected incidence calculated from a national stroke survey of 1,528 patients with adjustment for four major cardiovascular risk factors, only one ischemic stroke was observed against an expected 8.56 (P=.003) — an approximately eight-fold protective effect. Myocardial infarction rates were not reduced. A companion study of 219 severe FXI-deficient patients44 219 severe FXI-deficient patients
Salomon O et al., Thromb Haemost 2011; patients from the same Israeli cohort, age range 20–94 years found zero cases of deep-vein thrombosis against 4.68 expected from population data.

Bleeding risk in carriers and homozygotes is context-dependent and not reliably predicted by FXI plasma levels. A retrospective study of 198 FXI-deficient patients undergoing 252 procedures55 198 FXI-deficient patients undergoing 252 procedures
Handa et al., Blood Adv 2023; single academic medical center, 2011–2021; procedures included 143 vaginal deliveries, 63 cesarean sections, and 46 other operations identified personal bleeding history as the strongest predictor of perioperative bleeding (OR 5.92, P=.001), while FXI activity above 40 U/dL predicted reduced risk with 75% specificity. No epidural or spinal hematoma was observed in 174 neuraxial anesthesia procedures.

The Phe301Leu allele has been intensively studied in the Ashkenazi population. Over 180 F11 mutations are documented globally66 Over 180 F11 mutations are documented globally
Duga & Salomon, Semin Thromb Hemost 2009; as of 2013 the count exceeded 220 (Duga & Salomon, Semin Thromb Hemost 2013), but the combined carrier rate for both Ashkenazi founder mutations is approximately 1 in 8 Ashkenazi individuals — making this one of the most common hereditary coagulation disorders in this population.

Practical Actions

The critical window for intervention is before a procedure, not after a bleed begins. The oral cavity, pharynx, and genitourinary tract are the highest-risk sites — these tissues dissolve fibrin aggressively via local plasminogen activators, and FXI normally counteracts this through its activation of TAFI (thrombin-activatable fibrinolysis inhibitor). Without adequate FXI, dental extractions, tonsillectomy, prostate surgery, and urological procedures can trigger disproportionately prolonged bleeding in a significant minority of affected individuals.

First-line management for mucosal-site procedures is antifibrinolytic therapy (tranexamic acid), which directly counteracts the fibrinolytic environment. For major surgery, replacement therapy with fresh frozen plasma or FXI concentrate can raise FXI activity to the target range of 30–45 U/dL. A critical safety limit applies: FXI activity above 70 U/dL carries thrombotic risk — over-correcting this deficiency can paradoxically provoke the very clotting events that the deficiency otherwise protects against.

Interactions

The Type III (Phe301Leu) mutation creates a codominant partial deficiency in heterozygotes. When compound heterozygosity is present — one copy of Phe301Leu and one copy of a second F11 null allele (such as the Type II Glu135Stop frameshift, rs1057516616, or other rare F11 variants) — the result is severe hemophilia C indistinguishable in clinical severity from homozygosity.

The net coagulation balance is substantially altered when FXI deficiency coexists with prothrombotic variants. Individuals who also carry Factor V Leiden (rs6025) or the prothrombin G20210A variant (rs1799963) face a complex opposing coagulation phenotype — partial or complete FXI deficiency competing against an activated prothrombotic mechanism — that warrants specialist hematology assessment to determine individual risk.

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-carrier Normal

No F11 Phe301Leu mutation — normal FXI gene at this position

You do not carry the rs121965064 (Phe301Leu, Type III) mutation in the F11 gene. Your coagulation factor XI gene is intact at this position. The vast majority of people globally share this result — this mutation is highly enriched in Ashkenazi Jewish populations (2.4% allele frequency) but rare in all other populations. Other F11 variants, including the Type II Ashkenazi founder mutation and rare sporadic F11 mutations, are separate from this result and are assessed independently.

CT FXI Carrier (Type III) Carrier

One copy of the F11 Phe301Leu mutation — carrier for Factor XI deficiency

The Phe301Leu substitution impairs FXI dimerization. Your one intact F11 allele produces full-length, functional protein that compensates substantially — your total FXI activity typically falls in the partial deficiency range of 20–70 U/dL. This range spans a broad phenotypic spectrum: some carriers have never bled abnormally, while others experience significant post-procedural bleeding, particularly at high-fibrinolytic sites (mouth, nose, urinary tract).

Importantly, bleeding severity does not correlate reliably with FXI activity levels in the partial deficiency range. The Handa et al. 2023 study confirmed that personal bleeding history (OR 5.92) is a far stronger predictor of procedural bleeding than the FXI plasma level itself. A hematologist consultation before any invasive procedure allows risk stratification based on your personal history and specific FXI activity.

Carrier status also confers partial cardiovascular protection: while full protection against stroke and DVT is most robustly demonstrated in severe (homozygous) FXI deficiency, partial FXI reduction may offer a modest degree of thrombotic risk reduction — an area of active research interest.

If you are Ashkenazi Jewish, there is a meaningful chance that a biological relative also carries this mutation (combined Type II + III carrier rate ~1 in 8). If your partner also carries an F11 mutation, your children have a 25% chance of inheriting severe FXI deficiency (hemophilia C). Partner testing is recommended for family planning, especially within the Ashkenazi community.

CC Homozygous / Hemophilia C Homozygous

Two copies of the F11 Phe301Leu mutation — severe Factor XI deficiency (hemophilia C)

The double dose of Phe301Leu means both FXI alleles produce protein that fails to dimerize efficiently — roughly 92% of each allele's protein output is retained intracellularly, never reaching the bloodstream. Plasma FXI activity typically falls to 5–15 U/dL (normal: 60–150 U/dL). The residual activity in Type III homozygotes (~9.7% of normal, compared to ~1.2% in Type II homozygotes) does not reliably confer clinical protection: bleeding risk and management approach are essentially the same as for other severe FXI deficiency genotypes.

Spontaneous hemorrhage (joint bleeds, muscle bleeds) is uncommon because FXI amplifies thrombus propagation but is not essential for the initial hemostatic plug. Bleeding typically occurs after procedures at high-fibrinolytic sites:

  • Oral and pharyngeal procedures: dental extractions, tonsillectomy, adenoidectomy
  • Genitourinary procedures: prostatectomy, urological instrumentation, bladder operations; hematuria commonly follows these procedures
  • Childbirth: postpartum hemorrhage at approximately twice the general population rate; menorrhagia common in affected women
  • Major trauma: uncontrolled hemorrhage disproportionate to the injury

Critically, bleeding severity does not reliably correlate with FXI plasma activity in the severe range — personal bleeding history is the strongest clinical predictor. Some individuals with activity below 5 U/dL bleed minimally; others with 10–12 U/dL require replacement for routine dental work.

The cardiovascular protection is clinically significant: epidemiological studies document an approximately eight-fold reduction in ischemic stroke incidence and near-complete elimination of DVT risk in large severe-deficiency cohorts. This protection should factor into risk-benefit discussions if anticoagulation or thrombolysis is ever considered.

Management requires care at a hemophilia treatment center. Antifibrinolytic therapy (tranexamic acid) is first-line for mucosal-site procedures. Fresh frozen plasma (FFP) or FXI concentrate covers major surgery. A key dosing limit applies: FXI activity above 70 U/dL carries thrombotic risk — over-replacement in a severely deficient patient can paradoxically trigger the clotting events that the deficiency normally prevents.